|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Incretin based therapies:A novel treatment approach for non-alcoholic fatty liver disease显示文摘Non-alcoholic fatty liver disease is considered a hepatic manifestation of metabolic syndrome(MS).The current treatment of non-alcoholic fatty liver disease(NAFLD)principally includes amelioration of MS components by lifestyle modifications but the lack of success in their implementation and sustainment arises the need for effective pharmacological agent in fatty liver treatment.Incretins are gut derived hormones secreted into the circulation in response to nutrient ingestion that enhances glucose-stimulated insulin secretion.Glucagon-like peptide-1(GLP-1)is the most important incretin.Its receptor agonist and inhibitors of dipeptidyl peptidase-4(DPP-4)are used in treatment of type2 diabetes mellitus.DPP-4 serum activity and hepatic expression are shown to be elevated in several hepatic diseases.There are several experimental and clinical trials exploring the efficacy of incretin based therapies in NAFLD treatment.They suggest that GLP-1 analogues might have beneficial effect on hepatic steatosis acting as insulin sensitizers and directly by stimulating GLP-1 receptors expressed on hepatocytes.The use of DPP-4 inhibitors also results in hepatic fat reduction but the mechanism of action remains unclear.There is growing evidence that incretin based therapies have beneficial effects on hepatocytes,however further study analysis are needed to assess the long term effect of incretin based therapies on NAFLD. | Kristina Blaslov Tomislav Bulum Karin Zibar Lea Duvnjak | 2014 | World Journal of Gastroenterology2014，20，23： | 10 |
| 2 | Treatment approach to type 2 diabetes:Past,present and future显示文摘Type 2 diabetes mellitus(DM) is a lifelong metabolic disease, characterized by hyperglycaemia which gradually leads to the development and progression of vascular complications. It is recognized as a global burden disease, with substantial consequences on human health(fatality) as well as on health-care system costs. This review focuses on the topic of historical discovery and understanding the complexity of the disease in the field of pathophysiology, as well as development of the pharmacotherapy beyond insulin. The complex interplay of insulin secretion and insulin resistance developed from previously known 'ominous triumvirate' to 'ominous octet' indicate the implication of multiple organs in glucose metabolism. The pharmacological approach has progressed from biguanides to a wide spectrum of medications that seem to provide a beneficial effect on the cardiovascular system. Despite this, we are still not achieving the target treatment goals. Thus, the future should bring novel antidiabetic drug classes capable of acting on several levels simultaneously. In conclusion, given the raising burden of type 2 DM, the best present strategy that could contribute the most to the reduction of morbidity and mortality should be focused on primary prevention. | Kristina Blaslov Fran Stjepan Naranda Ivan Kruljac Ivana Pavlic Renar | 2018 | World Journal of Diabetes2018，9，12： | 7 |
| 3 | Relationship of vascular complications and exenatide therapy failure in type 2 diabetic patients显示文摘 | Blaslov K Zibar K Bulum T | 2013 | Acta Clin Croat2013，52，3： | 1 |
| 4 | Circulating dipeptidyl peptidase-4 activity is associated with diabetic retinopathy in type 1 diabetic patients 显示文摘 | BLASLOV K BULUM T DUVNJAK L | 2015 | Eur J Ophthalmol2015，25，4： | 1 |
| 5 | Pathophysiological factors in the development of diabetic nephropathy--new insights 显示文摘 | Blaslov K Bulum T Duvnjak L | 2014 | Acta Med Croatiea2014，68，2： | 1 |
| 6 | Pathophysiological fac- tors in the development of diabetic nephropathy-new insights显示文摘 | BLASLOV K BULUM T DUVNJAK L | 2014 | Acta Med Croatica2014，68，2： | 1 |
| 7 | The role of endothelial dysfunction driven by adipocitokines in the development and progression of microvascular complications in patients with type 1 and type 2 diabetes显示文摘 | Blaslov K Bulum T Duvnjak L | 2015 | Med Hypotheses2015，84，6： | 1 |
| 8 | Difference in glucagon-like peptide-1 concentrations between C-peptide negative type 1 diabetes mellitus patients and healthy controls显示文摘 | Zibar K Cuca JK Blaslov K | 2015 | Ann Clin Biochem2015，52，2： | 1 |
| 9 | Pathophysiological factors in the development of diabetic nephropathy-new insights 显示文摘 | Blaslov K Bulum T Duvnjak L | 2014 | Acta Med Croatica2014，68，2： | 1 |
| 10 | Pathophysiological factors in the development of diabetic nephropathy--new insights显示文摘 | Blaslov K Bulum T Duvnjak L | 2014 | Acta Med Croatica2014，68，2： | 1 |
| 11 | Pathophysiological factors in the development of diabetic nephropathy-new insights 显示文摘 | Blaslov K Bulum T Duvnjak L | 2014 | Acta Med Croatica2014，68，2： | 1 |
| 12 | Effect of exenatide therapy on hepatic fat quantity and hepatic biomarkers in type 2 diabetic patients显示文摘 | Kristina Blaslov Karin Zibar Tomislav Bulum Lea Duvnjak | 2013 | Clinics and Research in Hepatology and Gastroenterology2013，，： | 1 |
| 13 | Resting heart rate is associated with nonproliferative retinopathy in normoalbumlnuric type 1 diabetic pa- tients显示文摘 | Bulum T Blaslov K Duvnjak L | 2013 | J Clin Hypertens (Greenwich)2013，15，8： | 1 |
| 14 | Circulating dipepti- dyl peptidase-4 activity is associated with diabetic retinopathy in type 1 diabetic patients显示文摘 | BLASLOV K BULUM T DUVNJAK L | 2015 | European Journal of Ophthal- mology2015，25，4： | 1 |
| 15 | Impact of creatinine methodology on glomerular filtration rate estimation in diabetes显示文摘AIM To evaluate the influence of creatinine methodology on the performance of chronic kidney disease(CKD)-Epidemiology Collaboration Group-calculated estimated glomerular filtration rate(CKD-EPI-eGFR) for CKD diagnosis/staging in a large cohort of diabetic patients. METHODS Fasting blood samples were taken from diabetic patients attending our clinic for their regular annual examination, including laboratory measurement of serum creatinine and eGFR.RESULTS Our results indicated an overall excellent agreement in CKD staging(kappa = 0.918) between the Jaffé serum creatinine-and enzymatic serum creatinine-based CKDEPI-eGFR, with 9% of discordant cases. As compared to the enzymatic creatinine, the majority of discordances(8%) were positive, i.e., associated with the more advanced CKD stage re-classification, whereas only 1% of cases were negatively discordant if Jaffé creatinine was used for eGFR calculation. A minor proportion of the discordant cases(3.5%) were re-classified into clinically relevant CKD stage indicating mildly to moderately decreased kidney function(< 60 m L/min per 1.73 m^2). Significant acute and chronic hyperglycaemia, assessedas plasma glucose and Hb A1 c levels far above the recommended glycaemic goals, was associated with positively discordant cases. Due to a very low frequency, positive discordance is not likely to present a great burden for the health-care providers, while intensified medical care may actually be beneficial for the small number of discordant patients. On the other hand, a very low proportion of negatively discordant cases(1%) at the 60 m L/min per 1.73 m^2 eGFR level indicate a negligible possibility to miss the CKD diagnosis, which could be the most prominent clinical problem affecting patient care, considering high risk of CKD for adverse patient outcomes. CONCLUSION This study indicate that compensated Jaffé creatinine procedure, in spite of the glucose-dependent bias, is not inferior to enzymatic creatinine in CKD diagnosis/staging and therefore may provide a reliable and cost-effective tool for the renal function assessment in diabetic patients. | Marijana Vucic Lovrencic Vanja Radisic Biljak Kristina Blaslov Sandra Bozicevic Lea Smircic Duvnjak | 2017 | World Journal of Diabetes2017，8，5： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员